• Citer

Long-term follow-up of 2 patients treated with 90Y-rituximab radioimmunotherapy for relapse of nodular lymphocyte-predominant Hodgkin lymphoma

par Golstein, Sophie ;Muylle, Kristoff ;Vercruyssen, Marie ;Spilleboudt, Chloé ;de Wind, Alexandre;Bron, Dominique
Référence European journal of haematology, 101, 3, page (415-417)
Publication Publié, 2018-09

Article révisé par les pairs

• Détails
• Contenu

Résumé :

Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare lymphoma (<5% of Hodgkin’s lymphomas) predominantly affecting the middle-aged man, with an indolent behavior. Given the rare occurrence of this lymphoma, there are currently no clear guidelines for initial treatment or relapse. In this report, we present the follow-up of 2 patients treated by radioimmunotherapy for first relapse of their NLPHL. Both patients were initially treated with rituximab and relapsed 1 year after the end of their treatment.